HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has maintained a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) with a price target of $15.

March 07, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Werewolf Therapeutics maintains a Buy rating and a $15 price target from HC Wainwright & Co.
The maintenance of a Buy rating and a $15 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100